KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Other Non-Current Liabilities: 2012-2025

Historic Other Non-Current Liabilities for Sarepta Therapeutics (SRPT) over the last 12 years, with Sep 2025 value amounting to $36.3 million.

  • Sarepta Therapeutics' Other Non-Current Liabilities fell 23.42% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.3 million, marking a year-over-year decrease of 23.42%. This contributed to the annual value of $47.4 million for FY2024, which is 24.41% up from last year.
  • Latest data reveals that Sarepta Therapeutics reported Other Non-Current Liabilities of $36.3 million as of Q3 2025, which was down 23.42% from $47.4 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Other Non-Current Liabilities high stood at $50.8 million for Q1 2021, and its period low was $36.1 million during Q2 2023.
  • Over the past 3 years, Sarepta Therapeutics' median Other Non-Current Liabilities value was $47.4 million (recorded in 2025), while the average stood at $42.9 million.
  • In the last 5 years, Sarepta Therapeutics' Other Non-Current Liabilities soared by 395.71% in 2021 and then declined by 23.42% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $43.6 million in 2021, then declined by 15.37% to $36.9 million in 2022, then climbed by 3.25% to $38.1 million in 2023, then grew by 24.41% to $47.4 million in 2024, then declined by 23.42% to $36.3 million in 2025.
  • Its Other Non-Current Liabilities was $36.3 million in Q3 2025, compared to $47.4 million in Q2 2025 and $47.4 million in Q1 2025.